These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 15992698

  • 1. Cutaneous side-effects of kinase inhibitors and blocking antibodies.
    Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T.
    Lancet Oncol; 2005 Jul; 6(7):491-500. PubMed ID: 15992698
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Cutaneous side effects of sorafenib and sunitinib].
    Autier J, Mateus C, Wechsler J, Spatz A, Robert C.
    Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J, Drabick JJ.
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pulmonary toxicities of tyrosine kinase inhibitors.
    Peerzada MM, Spiro TP, Daw HA.
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):824-36. PubMed ID: 22252615
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
    Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A.
    J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
    [Abstract] [Full Text] [Related]

  • 10. Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer.
    Toubert ME, Vercellino L, Faugeron I, Lussato D, Hindie E, Bousquet G.
    Thyroid; 2011 Apr; 21(4):451-4. PubMed ID: 21385075
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.
    Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW.
    J Am Acad Dermatol; 2007 Feb; 56(2):317-26. PubMed ID: 17141360
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Imatinib: a designer drug, another cutaneous complication.
    Dickens E, Lewis F, Bienz N.
    Clin Exp Dermatol; 2009 Jul; 34(5):603-4. PubMed ID: 19486036
    [Abstract] [Full Text] [Related]

  • 16. Oral mucosal hyperpigmentation and horizontal melanonychia caused by imatinib.
    Steele JC, Triantafyllou A, Rajlawat BP, Field EA.
    Clin Exp Dermatol; 2012 Jun; 37(4):432-3. PubMed ID: 22420895
    [No Abstract] [Full Text] [Related]

  • 17. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
    Mitchell EP, Perez-Soler R, Van Cutsem E, Lacouture ME.
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):4-9. PubMed ID: 18154212
    [Abstract] [Full Text] [Related]

  • 18. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
    Lenihan DJ.
    J Clin Oncol; 2008 Nov 10; 26(32):5154-5. PubMed ID: 18838702
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Dermatologic symptoms associated with the multikinase inhibitor sorafenib.
    Robert C, Mateus C, Spatz A, Wechsler J, Escudier B.
    J Am Acad Dermatol; 2009 Feb 10; 60(2):299-305. PubMed ID: 19028406
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.